Position in NUVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,761,618
+$439,079 QoQ
Shares Held
643,734
+148.3% QoQ
Ownership
0.185%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Beacon Pointe Advisors, LLC holds $39,716,074 across 25 Biotechnology names. NUVB ranks #4 (7.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
19,460 | $15,035,574 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,894 | $7,990,386 | |
| 3 | INCY |
Incyte Corp
|
73,301 | $6,899,090 | |
| 4 | NUVB |
Nuvation Bio Inc.
This page
|
643,734 | $2,761,618 | |
| 5 | SMMT |
Summit Therapeutics Inc.
|
94,394 | $1,789,710 | |
| 6 | BNTX |
BioNTech SE
|
16,673 | $1,481,896 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
10,507 | $679,067 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
12,085 | $574,883 |
All Filings in NUVB
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,761,618 | 643,734 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,322,539 | 259,212 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $597,920 | 161,600 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $413,302 | 211,950 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $223,608 | 127,050 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $142,443 | 53,550 | Shares | Sole | 2025-02-14 | |
| 2024-03-31 | $78,988 | 21,700 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $32,767 | 21,700 | Shares | Sole | 2024-02-08 | |
| No filing history on record for this holder in this stock. | ||||||